Related scientific articles (all)

Neurofibromatosis type I with breast cancer: not only for women!

Authors : Lakshmaiah KC, Kumar AN, Purohit S, Viveka BK, Rajan KR, Zameer MA, Namitha P, Saini ML, Azim HA, Saini KS
Year : 2014
Journal : Hered Cancer Clin Pract
Volume : 12(1)
Pages : 5

Menopausal hormone therapy use in 17 European countries during the last decade.

Authors : Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S
Year : 2014
Journal : Maturitas
Volume : 79(3)
Pages : 287-91

Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Authors : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Year : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 346-7

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Authors : de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber Rd, Eidtmann H, Baselga J
Year : 2014
Journal : Lancet Oncol
Volume : 15(10)
Pages : 1137-46

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.

Authors : Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Year : 2014
Journal : Oncologist
Volume : 19(4)
Pages : 348-9

Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Authors : Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart-Gebhart M, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C
Year : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1544-50

Supportive care is a constant state of changing: we need to adjust for it.

Authors : Klastersky J
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(4)
Pages : 371

Reply to C. Fontanella et Al.

Authors : Azim HA, de Azambuja E, Agbor-Tarh D, Bradbury I
Year : 2014
Journal : J. Clin. Oncol.
Volume : 32(30)
Pages : 3459

Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO).

Authors : Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart-Gebhart M
Year : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1558-62

The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?

Authors : Piccart-Gebhart M
Year : 2014
Journal : J. Clin. Oncol.
Volume : 32(4)
Pages : 347-54

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes.

Authors : Garaud S, Gu-Trantien C, Lodewyckx JN, Boisson A, De Silva P, Buisseret L, Migliori E, Libin M, Naveaux C, Duvillier H, Willard-Gallo K
Year : 2014
Journal : J Vis Exp
Volume : null(94)

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Authors : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Year : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1959-65

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Authors : Criscitiello C, Azim HA, de Azambuja E, Rubio IT
Year : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 910-1

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

Authors : McCullough AE, + collaborators (among others :, Piccart-Gebhart M, Viale G
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pages : 485-92

Anticancer drug development: moving away from the old habits.

Authors : Ades F, Zardavas D, Aftimos P, Awada A
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(3)
Pages : 334-9

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Authors : Viale G, Slaets L, Bogaerts J, Rutgers E, + collaborators (among others :, Piccart-Gebhart M, Cardoso F
Year : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 816-23

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Authors : Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 148(3)
Pages : 553-61

Fertility issues in young breast cancer patients: what women want.

Authors : Lambertini M, Pinto AC, Del Mastro L
Year : 2014
Journal : J Thorac Dis
Volume : 6(6)
Pages : 584-8

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Authors : Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart-Gebhart M
Year : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 824-31

Belgian Society of Medical oncology (BSMO - task force on breast cancer survivorship)

Authors : de Azambuja E, Azim HA, Buisseret L, Langenaeken C, Tkint de Roodenbeke D
Year : 2014
Journal : Belgian J Medical Oncology
Volume : 7(5)
Pages : 142-155